Common Contracts

4 similar Underwriting Agreement contracts by EyePoint Pharmaceuticals, Inc., Icad Inc, Mind Medicine (MindMed) Inc., Seelos Therapeutics, Inc.

Mind Medicine (MindMed) Inc. 16,666,667 Common Shares (no par value per share) Underwriting Agreement
Underwriting Agreement • March 11th, 2024 • Mind Medicine (MindMed) Inc. • Medicinal chemicals & botanical products • New York

Mind Medicine (MindMed) Inc., a corporation incorporated under the laws of the Province of British Columbia (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 16,666,667 common shares, having no par value per share (“Common Shares”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the context requires.

19,354,840 Shares of Common Stock SEELOS THERAPEUTICS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • May 21st, 2021 • Seelos Therapeutics, Inc. • Pharmaceutical preparations • New York

Seelos Therapeutics, Inc., a corporation organized and existing under the laws of the State of Nevada (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 19,354,840 shares (the “Firm Shares”) of its common stock, par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 2,903,226 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).

1,222,222 Shares of Common Stock ICAD, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • March 4th, 2021 • Icad Inc • Surgical & medical instruments & apparatus • New York

iCAD, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 1,222,222 shares (the “Firm Shares”) of its common stock, par value $0.01 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 171,516 shares (the “Additional Shares”) of Common Stock at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim Securities”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).

10,526,500 Shares of Common Stock EYEPOINT PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT March 28, 2019
Underwriting Agreement • April 1st, 2019 • EyePoint Pharmaceuticals, Inc. • Laboratory analytical instruments • New York

EyePoint Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,526,500 shares of its common stock (the “Firm Shares”), par value $0.001 per share (the “Common Stock”). The Company also proposes to issue and sell to the several Underwriters up to an additional 1,578,975 shares of Common Stock (the “Additional Shares”) at the option of the Underwriters as provided in Section 2(c) below. The Firm Shares and any Additional Shares purchased by the Underwriters are referred to herein as the “Shares.” Guggenheim Securities, LLC (“Guggenheim”) is acting as representative (the “Representative”) of the several Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).